Melanoma Research Victoria

Source: OncLive, July 2019 The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial (NCT03273153).1 The safety profile observed with the combination regimen was consistent with the known safety profiles […]

Read the full story

Source: Targeted Oncology, July 2019 The phase III IMspire170 trial (NCT03273153) failed to meet its primary endpoint according to topline results from the study. The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma. The safety profile observed with the combination […]

Read the full story

Source: Specialty Pharmacy Times, July 2019 First-line treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) provided overall survival (OS) and long-term progression-free survival (PFS) benefits in patients with unresectable or metastatic BRAF-mutation positive melanoma, according to a pooled analysis of 2 phase 3 trials. Metastatic melanoma often results in poor prognosis for patients who are diagnosed. Each […]

Read the full story

Source: Karolinska Institutet EN, July 2019 The standard treatment for aggressive skin cancer is to surgically remove the tumour. Researchers at Karolinska Institutet in Sweden now show that a 2 cm operational margin is sufficient, as opposed to the close to 4 cm margin previously applied by surgeons. For the study, which is published in The […]

Read the full story